Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
| ▸ | ITK | Q08881 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.31 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5027605 | 0.88 | ALDH1A1 (0.46) | HPGDMAPK1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL5029995 | 0.86 | ALDH1A1 (0.44) | HPGDMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL6428814 | 0.86 | KDM4E (0.43) | HPGDSSPRHPGDL3MBTL1ALDH1A1 | |
| SCHEMBL5034404 | 0.86 | HPGD (0.43) | HPGDMAPK1ALDH1A1 | |
| SCHEMBL13927767 | 0.86 | HPGDS (0.38) | HPGDSSPRITKHPGDMAPK1 | |
| SCHEMBL5034299 | 0.85 | AURKA (0.33) | ALDH1A1GPR52 | |
| SCHEMBL5034297 | 0.85 | AURKA (0.33) | ALDH1A1GPR52 | |
| SCHEMBL6425792 | 0.85 | HPGDS (0.44) | HPGDSSPRHPGDMAPK1ALDH1A1 | |
| SCHEMBL6426848 | 0.84 | CHEK1 (0.40) | HPGDSHPGDALDH1A1CYP3A4 | |
| SCHEMBL5031127 | 0.84 | HPGDS (0.36) | HPGDSSPRHPGDMAPK1KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | HPGDS 3567/4885SPR 3128/4885ITK 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.